3-Month Visual And Refractive Outcomes In Refractive Lens Exchange With Artiols®

Purpose: To report the three-month visual outcomes and Patient‐reported outcome measures (PROMs) of patients undergoing clear lens excahnge with the ArtIOLs®.
Setting: University Hospital Gießen and Marburg, Marburg, Germany
Methods: This retrospective, non-randomised, single-centre study analysed the efficacy and safety of the combination of ArtIOLs®40 (EDF) and ArtIOLs® 70 (FVR) lens in 11 patients who underwent refractive lens exchange (RLE) between December 2023 and February 2025. Follow-up examinations were conducted at least three months after treatment, including refraction and visual acuity at far, intermediate and near distances. The subjects were selected from the existing patient pool of the eye clinic of the University Hospital Marburg. The eligible patients were identified by a review of the clinic’s surgical reports. Relevant pre- and postoperative clinical data were systematically extracted from the written patient records, anonymised and analysed.
Results: The preop SEQ was +2.37±0.53 (2.00 to 2.74 D). Preop CDVA was 20/20 or better in 82 % of eyes. At 3 months, postop accuracy of SEQ to intended showed 94% of eyes within ±0.50 D and 100 % within ±1.00D. Binocular UDVA was 20/20 or better in 76 % and 20/25 or better in 100 % of eyes. The binocular UNVA for 40 cm was 20/20 or better in 88 % and 20/25 or better in 100 % of eyes and binokular UIVA for 66 cm 20/20 or better in 94 % and 20/25 or better in 100 % of eyes. Ten (91%) patients achieved spectacle independence for far and intermediate vision, with only one patient requiring usually glasses for near vision.
Conclusions: ArtIOL® lens implantation for refractive lens exchange delivers excellent visual and refractive outcomes, providing high-quality vision at near (40 cm), intermediate (66 cm), and distance.